Condensed Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Product sales	$ 543,145	$ 694,329	$ 1,714,340	$ 2,183,626
License fee and other revenues	266,096	250,000	302,324	250,000
Research and development	89,838	238,369	284,397	823,861
Total revenues	899,079	1,182,698	2,301,061	3,257,487
Costs and Expenses:
Costs of goods sold	337,675	72,771	460,458	218,040
Research and development	13,298,860	10,385,422	40,473,666	30,142,289
Sales and marketing	248,425	285,708	778,642	689,140
General and administrative	1,580,824	1,564,536	4,960,959	7,239,764
Total costs and expenses	15,465,784	12,308,437	46,673,725	38,289,233
Operating loss	(14,566,705)	(11,125,739)	(44,372,664)	(35,031,746)
Interest expense	(1,369,955)	(720,795)	(4,109,866)	(720,795)
Interest and other income	81,911	32,838	257,631	69,126
Foreign currency transaction (loss) gain, net	(38,699)	28,873	(42,210)	29,035
Loss before income tax benefit (expense)	(15,893,448)	(11,784,823)	(48,267,109)	(35,654,380)
Income tax benefit (expense)	1,871,772	(3,327)	5,056,772	(42,182)
Net loss	(14,021,676)	(11,788,150)	(43,210,337)	(35,696,562)
Less: Net loss attributable to noncontrolling interest	(25,631)	(32,003)	(74,420)	(94,760)
Net loss attributable to Immunomedics, Inc. stockholders	$ (13,996,045)	$ (11,756,147)	$ (43,135,917)	$ (35,601,802)
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted):	$ (0.15)	$ (0.13)	$ (0.46)	$ (0.38)
Weighted average shares used to calculate loss per common share, (basic and diluted)	94,748,252	93,351,708	94,669,326	93,201,307
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	$ 72,837	$ (253,502)	$ 35,566	$ (511,335)
Unrealized gain on securities available for sale securities	90,925	16,220	11,658	5,769
Other comprehensive income (loss)	163,762	(237,282)	47,224	(505,566)
Comprehensive loss	(13,857,914)	(12,025,432)	(43,163,113)	(36,202,128)
Less comprehensive loss attributable to noncontrolling interest	(25,631)	(32,003)	(74,420)	(94,760)
Comprehensive loss attributable to Immunomedics, Inc. stockholders	$ (13,832,283)	$ (11,993,429)	$ (43,088,693)	$ (36,107,368)